Dexcom (DXCM) Long-Term Deferred Tax (2020 - 2026)

Dexcom (DXCM) has 7 years of Long-Term Deferred Tax data on file, last reported at $296.1 million in Q1 2026.

• On a quarterly basis, Long-Term Deferred Tax fell 39.24% year-over-year to $296.1 million in Q1 2026; TTM through Mar 2026 was $296.1 million, a 39.24% decrease from a year earlier, with the FY2025 full-year figure at $295.6 million, down 38.57% from the prior year.
• Long-Term Deferred Tax for Q1 2026 stood at $296.1 million, roughly flat from $295.6 million in the prior quarter.
• Over the last five years, Long-Term Deferred Tax for DXCM reached as high as $501.3 million in Q3 2023 and fell as low as $290.8 million in Q1 2022.
• Historically, Long-Term Deferred Tax has averaged $401.5 million across 5 years, with a median of $417.0 million in 2023.
• Across the five-year window, Long-Term Deferred Tax surged 58.25% in 2022 and plunged 39.24% in 2026, its largest moves.
• Year by year, Long-Term Deferred Tax stood at $341.2 million in 2022, then gained by 22.92% to $419.4 million in 2023, then rose by 14.74% to $481.2 million in 2024, then slumped by 38.57% to $295.6 million in 2025, then gained by 0.17% to $296.1 million in 2026.
• Per Business Quant data, the three most recent Long-Term Deferred Tax figures were $296.1 million in Q1 2026, $295.6 million in Q4 2025, and $375.6 million in Q3 2025.